Rossari Biotech Q1 FY27 Revenue Up 28% to ₹697.2 Cr
Rossari Biotech announced its financial results for the quarter ended June 30, 2026. Consolidated revenue from operations grew 28% year-on-year to ₹697.2 crore, reaching its highest-ever quarterly revenue. EBITDA improved by 19% to ₹80.6 crore, though the EBITDA margin slightly decreased to 11.6% from 12.5%. Profit After Tax (PAT) saw a 4% increase to ₹35.1 crore. Standalone revenue also surged by 32% to ₹482.3 crore. The company highlighted strong momentum in domestic and international businesses, driven by its HPPC, TSC, and AHN segments. Key developments include establishing a new greenfield blending facility in Thailand to serve Southeast Asia and completing the sale of its Andheri office as part of non-core asset monetization.
Key Highlights
- Q1 FY27 consolidated revenue reached highest-ever ₹697.2 crore, up 28% YoY.
- Consolidated EBITDA grew 19% to ₹80.6 crore; PAT up 4% to ₹35.1 crore.
- Standalone revenue increased 32% YoY to ₹482.3 crore.
- Established a new blending facility in Thailand to boost Southeast Asia presence.
- Completed sale of Andheri office, continuing non-core asset monetization.
Price Impact
More from ROSSARI